Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference

RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing…

RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the H.C. Wainwright BioConnect 2021 Conference, being held virtually January 11-14, 2021.

A replay of the pre-recorded fireside chat will be available beginning Monday, January 11, at 6:00 am E.T. and can be accessed by visiting the Events and Webcasts section of the Company’s website: http://investors.proventionbio.com/events. The webcast will be archived on the Company’s website for 30 days following the presentation.

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company has submitted a Biologics License Application (BLA) to the FDA for its lead investigational drug candidate, teplizumab, for the delay or prevention of clinical type 1 diabetes in at-risk individuals. The Company’s pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the Company’s website in the «News» section. Accordingly, investors should monitor this portion of the Company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contact:

Sam Martin, Argot Partners

sam@argotpartners.com

212-600-1902

Media Contact:

Lori Rosen, LDR Communications

lori@ldrcommunications.com

917-553-6808

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-participate-in-the-hc-wainwright-virtual-bioconnect-conference-301202297.html

SOURCE Provention Bio, Inc.